Livagen: Research Overview

Livagen is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Ala (KEDA). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues through directed chemical synthesis guided by amino acid analysis of natural polypeptide fractions extracted from liver tissue. Livagen has no FDA, EMA, or comparable Western regulatory approval and is not an approved pharmaceutical outside of Russia. It is sold in some markets as a research compound or food supplement.

What is Livagen?

Livagen (KEDA) belongs to the Khavinson peptide bioregulator family, a class of short organ-specific peptides hypothesized to act as tissue-targeted gene expression regulators. The premise of this peptide class is that each short sequence preferentially influences the chromatin conformation and transcriptional output of the organ from which the parent polypeptide complex was originally derived — in Livagen's case, the liver. Livagen is presented commercially as a lyophilized powder with reported molecular weight around 488 Da.

Proposed Mechanism

The Khavinson group proposes that KEDA binds to specific short DNA sequences in the minor groove of the double helix, inducing partial heterochromatin decondensation in hepatocytes. This is postulated to restore transcriptional access to genes that become progressively silenced during aging. In vitro hepatocyte culture experiments reported that nanomolar concentrations of the tetrapeptide increased protein synthesis rates in cells isolated from aged rats, partially restoring rates toward those observed in young rat hepatocytes. The compound has also been described as an inhibitor of enkephalin-degrading enzymes, though this observation has not been independently replicated.

Research Summary

A PubMed-indexed study (PMID 15926314) investigated protein synthesis rhythms in cultured hepatocytes from rats of different ages and reported that the KEDA tetrapeptide increased synthetic activity particularly in cells from old animals. A second study (PMID 12577697) examined organotypic liver cultures and reported morphological and functional changes consistent with a hepatoprotective effect following Livagen exposure. A 2020 paper (PMID 32362099) investigated the combined influence of a polypeptide liver complex and the KEDA tetrapeptide on physiological parameters in both normal aging and experimentally induced liver pathology models in animals, reporting hepatoprotective, immunoprotective, and apparent anti-aging properties.

Research on Livagen is concentrated in a single Russian research group; independent Western replication is limited. The published literature consists largely of in vitro and animal model studies from the Khavinson laboratory. No placebo-controlled human trials have been reported in the indexed Western literature, and no regulatory body outside Russia has reviewed Livagen for efficacy or safety. The evidence base is insufficient to draw conclusions about clinical benefit in humans.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

No formally validated human dose has been established in Western trials. Russian-language supplement documentation and commercial sources reference subcutaneous or intramuscular doses in the range of 0.5-1 mg per day over a 10-day course, repeated one to two times per year. These figures are not derived from dose-escalation studies and should not be treated as medically authoritative.

Frequently Asked Questions

What distinguishes Livagen from other liver-support supplements?

Livagen is a precisely defined short peptide rather than a complex botanical or nutrient mixture. Its proposed mechanism — direct DNA binding and chromatin modulation — is distinct from antioxidant or anti-inflammatory pathways described for most commercial liver supplements. However, this mechanism remains hypothesis-level in humans; clinical evidence is absent.

Is Livagen available as an approved drug?

Not in Western markets. In Russia, the parent polypeptide complex Ventvil is used clinically and the KEDA tetrapeptide has been studied alongside it. Livagen as a standalone synthetic tetrapeptide is not an approved pharmaceutical in any Western jurisdiction.

Can Livagen reverse liver damage?

There is no evidence from controlled human trials to support this claim. Animal model results from a single Russian research group showing attenuation of experimental hepatitis or fibrosis cannot responsibly be extrapolated to clinical liver disease treatment in humans.

References

1. [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages: effect of the peptide livagen]. PMID 15926314. https://pubmed.ncbi.nlm.nih.gov/15926314/

2. [Functional morphology of an organotypic liver culture exposed to the peptide livagen]. PMID 12577697. https://pubmed.ncbi.nlm.nih.gov/12577697/

3. [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology]. PMID 32362099. https://pubmed.ncbi.nlm.nih.gov/32362099/